Petros C. Karakousis

What is he best known for?

The fields of study he is best known for:

• Internal medicine
• Gene
• Bacteria

His primary areas of investigation include Mycobacterium tuberculosis, Microbiology, Tuberculosis, Isoniazid and Latent tuberculosis. His study in Mycobacterium tuberculosis is interdisciplinary in nature, drawing from both Drug resistance and In vivo. His Microbiology study combines topics in areas such as Chemokine, Stringent response, Operon and Virulence.

The study incorporates disciplines such as Virology, Internal medicine, Disease and Hazard ratio in addition to Tuberculosis. His Isoniazid research is multidisciplinary, incorporating elements of Regimen and Pharmacology. His Latent tuberculosis study incorporates themes from Granuloma, Immunology and Antibiotics.

His most cited work include:

• Dormancy Phenotype Displayed by Extracellular Mycobacterium tuberculosis within Artificial Granulomas in Mice (216 citations)
• Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy (168 citations)
• Localization of pigment epithelium derived factor (PEDF) in developing and adult human ocular tissues. (126 citations)

What are the main themes of his work throughout his whole career to date?

Petros C. Karakousis mainly focuses on Mycobacterium tuberculosis, Tuberculosis, Microbiology, Immunology and Isoniazid. His studies in Mycobacterium tuberculosis integrate themes in fields like Gene, Mutant, Virulence and Drug resistance. His research integrates issues of Internal medicine, Antibiotics, Pharmacology and Virology in his study of Tuberculosis.

The various areas that he examines in his Pharmacology study include Rifapentine and Regimen. His study looks at the relationship between Microbiology and topics such as Chemokine, which overlap with Proinflammatory cytokine. He works mostly in the field of Isoniazid, limiting it down to topics relating to Guinea pig and, in certain cases, Streptomycin.

He most often published in these fields:

• Mycobacterium tuberculosis (96.46%)
• Tuberculosis (91.92%)
• Microbiology (46.46%)

What were the highlights of his more recent work (between 2018-2021)?

• Tuberculosis (91.92%)
• Mycobacterium tuberculosis (96.46%)
• Internal medicine (19.70%)

In recent papers he was focusing on the following fields of study:

His main research concerns Tuberculosis, Mycobacterium tuberculosis, Internal medicine, Immunology and Immune system. His work carried out in the field of Tuberculosis brings together such families of science as Atorvastatin and Virology. His Mycobacterium tuberculosis study integrates concerns from other disciplines, such as Microbiology, Listeria monocytogenes, microRNA, Isoniazid and Human pathogen.

His Microbiology research includes themes of Nontuberculous mycobacteria and Intracellular parasite. Petros C. Karakousis has included themes like Bacteria, Stringent response, Mutant and Metabolism in his Isoniazid study. His Immune system research incorporates themes from Mycobacterium, Statin, Gene, Hepatitis virus and Transposable element.

Between 2018 and 2021, his most popular works were:

• Inhibiting the stringent response blocks Mycobacterium tuberculosis entry into quiescence and reduces persistence (29 citations)
• Inhibiting the stringent response blocks Mycobacterium tuberculosis entry into quiescence and reduces persistence (29 citations)
• Stability and Viability of SARS-CoV-2. (28 citations)

In his most recent research, the most cited papers focused on:

• Internal medicine
• Gene
• Bacteria

The scientist’s investigation covers issues in Tuberculosis, Mycobacterium tuberculosis, Microbiology, Pharmacology and Virology. Petros C. Karakousis integrates several fields in his works, including Tuberculosis and Repurposing. His studies deal with areas such as Stringent response, Mutant, Bacteria, Isoniazid and Metabolism as well as Mycobacterium tuberculosis.

Petros C. Karakousis combines subjects such as Altered metabolism and Nontuberculous mycobacteria with his study of Microbiology. His study in Pharmacology is interdisciplinary in nature, drawing from both Statin, Pyrazinamide, Pravastatin and Adjunctive treatment. In general Virology study, his work on Hepatitis B often relates to the realm of 2019-20 coronavirus outbreak, Sars virus, Severe acute respiratory syndrome coronavirus 2 and Coronavirus Infections, thereby connecting several areas of interest.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.